Because of the differential role of FGFR1 in various stages of NAFLD, it is critical to evaluate organs and cell types that express the RTK to improve the viability of RTK inhibition therapy in managing the disease. The gene discussed is FGFR1; the disease is metabolic dysfunction-associated steatotic liver disease.